Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: We have several concerns about
the study of Dr Levine and colleagues.1 First,
the high proportion of patients with aPL (41%) raises questions about the
specificity of the tests they used. Second, the average age of the patients
was significantly higher than that of those in most prior studies of antiphospholipid
syndrome. Third, the authors achieved a relatively low mean international
normalized ratio (INR) among the patients in the high-intensity group.
Ruiz-Irastorza G, Khamashta MA, Hughes GRV. Antiphospholipid Antibodies and Risk for Recurrent Vascular Events. JAMA. 2004;291(22):2701. doi:10.1001/jama.291.22.2701-b